Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 92, Issue 1, Pages 94-108
Publisher
Wiley
Online
2016-12-19
DOI
10.1002/ajh.24607
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances
- (2016) T. Barbui et al. BLOOD REVIEWS
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discriminating between essential thrombocythemia and masked polycythemia vera inJAK2mutated patients
- (2014) Tiziano Barbui et al. AMERICAN JOURNAL OF HEMATOLOGY
- Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
- (2014) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia
- (2014) G. Finazzi et al. BLOOD
- Presence of calreticulin mutations in JAK2-negative polycythemia vera
- (2014) J. Broseus et al. BLOOD
- In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
- (2014) T. Barbui et al. BLOOD
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- Calreticulin mutations and long-term survival in essential thrombocythemia
- (2014) A Tefferi et al. LEUKEMIA
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
- (2014) A Tefferi et al. LEUKEMIA
- Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
- (2014) Bruno Cassinat et al. NEW ENGLAND JOURNAL OF MEDICINE
- Masked polycythemia Vera (mPV): Results of an international study
- (2013) Tiziano Barbui et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
- (2013) G. Rotunno et al. BLOOD
- JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
- (2013) E. Rumi et al. BLOOD
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
- (2013) E. T. Kuriakose et al. HAEMATOLOGICA
- Personalized management of essential thrombocythemia—application of recent evidence to clinical practice
- (2013) A Tefferi et al. LEUKEMIA
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Rethinking the diagnostic criteria of polycythemia vera
- (2013) T Barbui et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
- (2012) S. Pascale et al. BLOOD
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- (2012) T. Barbui et al. BLOOD
- A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
- (2012) F. Passamonti et al. BLOOD
- Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients
- (2012) Gilles Bonicelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- GermlineJAK2Mutation in a Family with Hereditary Thrombocytosis
- (2012) Adam J. Mead et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
- (2011) A. Alvarez-Larran et al. BLOOD
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
- (2011) A. Carobbio et al. BLOOD
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count
- (2010) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs
- (2010) Elena Crisà et al. ANNALS OF HEMATOLOGY
- Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
- (2010) A. Alvarez-Larran et al. BLOOD
- Clinical utility of routineMPLexon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis
- (2010) Elaine M. Boyd et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
- (2010) A Tefferi LEUKEMIA
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- (2010) F Passamonti et al. LEUKEMIA
- Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations
- (2009) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
- (2009) E. Voskaridou et al. BLOOD
- Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies
- (2009) Naseema Gangat et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia
- (2009) K. Liu et al. HAEMATOLOGICA
- Two rare MPL gene mutations in patients with essential thrombocythemia
- (2009) Haruhiko Ohashi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia
- (2009) Juergen Thiele et al. JOURNAL OF CLINICAL ONCOLOGY
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies
- (2009) F. PASSAMONTI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Mutant Molecules of Interest in Myeloproliferative Neoplasms: Introduction
- (2008) Ayalew Tefferi ACTA HAEMATOLOGICA
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
- (2008) A. M. Vannucchi et al. BLOOD
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
- (2008) P. A. Beer et al. BLOOD
- Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis
- (2008) Andrew J K Östör CLINICAL RHEUMATOLOGY
- JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
- (2008) A. H. Schmitt-Graeff et al. HAEMATOLOGICA
- The Role of Clopidogrel and Acetylsalicylic Acid in the Prevention of Early-Phase Graft Occlusion Due to Reactive Thrombocytosis after Coronary Artery Bypass Operation
- (2008) Ilyas Kayacioglu et al. HEART SURGERY FORUM
- Evidence and expertise in the management of polycythemia vera and essential thrombocythemia
- (2008) G Finazzi et al. LEUKEMIA
- Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
- (2008) J-J Kiladjian et al. LEUKEMIA
- TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients
- (2008) T L Lasho et al. LEUKEMIA
- Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
- (2008) A M Vannucchi et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation